Collegium Pharmaceutical, Inc.

NasdaqGS COLL

Collegium Pharmaceutical, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 12.08

Collegium Pharmaceutical, Inc. Price to Earnings Ratio (P/E) is 12.08 on January 14, 2025, a -44.32% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Collegium Pharmaceutical, Inc. 52-week high Price to Earnings Ratio (P/E) is 27.43 on March 27, 2024, which is 127.13% above the current Price to Earnings Ratio (P/E).
  • Collegium Pharmaceutical, Inc. 52-week low Price to Earnings Ratio (P/E) is 10.16 on July 10, 2024, which is -15.89% below the current Price to Earnings Ratio (P/E).
  • Collegium Pharmaceutical, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 14.33.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NasdaqGS: COLL

Collegium Pharmaceutical, Inc.

CEO Mr. Vikram Karnani
IPO Date May 7, 2015
Location United States
Headquarters 100 Technology Center Drive
Employees 197
Sector Health Care
Industries
Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Similar companies

ITCI

Intra-Cellular Therapies, Inc.

USD 126.89

-0.24%

EOLS

Evolus, Inc.

USD 9.47

-3.37%

RGC

Regencell Bioscience Holdings Limited

USD 4.86

-4.71%

ALKS

Alkermes plc

USD 28.50

0.53%

PCRX

Pacira BioSciences, Inc.

USD 20.55

-2.74%

PBH

Prestige Consumer Healthcare Inc.

USD 75.78

1.54%

ANIP

ANI Pharmaceuticals, Inc.

USD 54.16

0.43%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

AMPH

Amphastar Pharmaceuticals, Inc.

USD 38.48

1.48%

PROC

Procaps Group S.A.

USD 1.76

7.98%

StockViz Staff

January 15, 2025

Any question? Send us an email